Quantcast

Latest Inovio Pharmaceuticals Inc. Stories

2014-06-17 04:21:35

Expanded License Includes New Product Candidates for Cancer, Infectious Diseases and Novel Immune Activators BLUE BELL, Pa., June 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research...

2014-06-16 04:21:37

BLUE BELL, Pa., June 16, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President & CEO, Dr. J. Joseph Kim, will participate in a panel at the Piper Jaffray GenomeRx Symposium on June 23 to discuss Inovio's leadership in the advancement of novel DNA-based immune therapies. Inovio management will also present a corporate overview at the 2014 BIO International Convention hosted by the Biotechnology Industry Organization (BIO). This year's...

2014-06-11 08:30:52

Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading...

2014-06-10 04:22:14

Inovio Targets Most Rapidly Increasing Cancer in Men BLUE BELL, Pa., June 10, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune...

2014-05-30 04:22:21

BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO." As filed on May 22, 2014, the Company's stockholders approved the proposal of a reverse...

2014-05-27 04:21:46

BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license...

2014-05-27 04:21:43

Protection Data Presented at the 17th Annual Meeting of the American Society of Gene & Cell Therapy BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was...

2014-05-23 04:20:51

BLUE BELL, Pa., May 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio's common stock, where each 4 shares of issued and outstanding common stock and equivalents...

2014-05-21 04:21:27

BLUE BELL, Pa., May 21, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 at the Grand Hyatt Hotel in New York City. Inovio PresentationMonday, June 2, 20148:00 AM ET A live webcast of Dr. Kim's presentation can be accessed at the following URL: http://wsw.com/webcast/jeff82/INO. An archived version of...

2014-05-13 04:22:33

BLUE BELL, Pa., May 13, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College. Dr. Wang is a pioneer in the field of DNA therapies, having worked closely with Dr. David Weiner at the University of Pennsylvania. Dr. Wang was the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related